Related references
Note: Only part of the references are listed.Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia
S. Fujita et al.
LEUKEMIA (2018)
EZH2 inhibitors: a patent review (2014-2016)
Giulia Stazi et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2017)
DUAL INHIBITION OF EZH2 AND HDAC IS SYNERGISTIC IN EZH2 DYSREGULATED LYMPHOMAS
J.K. Lue et al.
HEMATOLOGICAL ONCOLOGY (2017)
PRELIMINARY EVIDENCE OF A MOLECULAR PREDICTOR OF TAZEMETOSTAT RESPONSE, BEYOND EZH2 MUTATION, IN NHL PATIENTS VIA CHARACTERIZATION OF ARCHIVE TUMOR AND CIRCULATING TUMOR DNA
S.J. Blakemore et al.
HEMATOLOGICAL ONCOLOGY (2017)
INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS
F. Morschhauser et al.
HEMATOLOGICAL ONCOLOGY (2017)
Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy
Ying Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) Methyltransferase
Andreas Lingel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL
Dorothy Brach et al.
MOLECULAR CANCER THERAPEUTICS (2017)
An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED
Wei Qi et al.
NATURE CHEMICAL BIOLOGY (2017)
The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex
Yupeng He et al.
NATURE CHEMICAL BIOLOGY (2017)
EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop
Wendy Beguelin et al.
NATURE COMMUNICATIONS (2017)
Discovery and Molecular Basis of a Diverse Set of Polycomb Repressive Complex 2 Inhibitors Recognition by EED
Ling Li et al.
PLOS ONE (2017)
Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor
Daisuke Honma et al.
CANCER SCIENCE (2017)
Activity of the EZH2 inhibitor tazemetostat as a monotherapy and in combination with multiple myeloma therapies in preclinical models
Allison E. Drew et al.
CANCER RESEARCH (2017)
Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors
V. Gibaja et al.
ONCOGENE (2016)
JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis
Jean Grisouard et al.
BLOOD (2016)
EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis
Wendy Beguelin et al.
CANCER CELL (2016)
Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas
Rishi G. Vaswani et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors
Pei-Pei Kung et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer
Haikuo Zhang et al.
CANCER DISCOVERY (2016)
Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma
Satoshi Kawano et al.
PLOS ONE (2016)
Discovery, design, and synthesis of indole-based EZH2 inhibitors
Victor S. Gehling et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus™
Feng Sun et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Targeting EZH2 and PRC2 dependence as novel anticancer therapy
Bowen Xu et al.
EXPERIMENTAL HEMATOLOGY (2015)
EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity
John E. Campbell et al.
ACS MEDICINAL CHEMISTRY LETTERS (2015)
Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors
Theresa Baker et al.
ONCOTARGET (2015)
Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia
Bowen Xu et al.
BLOOD (2015)
EZH2 Inhibitor Efficacy in Non-Hodgkin's Lymphoma Does Not Require Suppression of H3K27 Monomethylation
William D. Bradley et al.
CHEMISTRY & BIOLOGY (2014)
Histone variants: dynamic punctuation in transcription
Christopher M. Weber et al.
GENES & DEVELOPMENT (2014)
Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
Sarah K. Knutson et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas
Sarah K. Knutson et al.
PLOS ONE (2014)
Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis
Katerina Hatzi et al.
TRENDS IN MOLECULAR MEDICINE (2014)
EZH2 mutations are frequent and represent an early event in follicular lymphoma
Csaba Boedoer et al.
BLOOD (2013)
EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
Wendy Beguelin et al.
CANCER CELL (2013)
Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth
Shivani Garapaty-Rao et al.
CHEMISTRY & BIOLOGY (2013)
Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis
Marieta Caganova et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer
Woojin Kim et al.
NATURE CHEMICAL BIOLOGY (2013)
Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
Sarah K. Knutson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Germinal Centers
Gabriel D. Victora et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 30 (2012)
Cancer Epigenetics: From Mechanism to Therapy
Mark A. Dawson et al.
CELL (2012)
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe et al.
NATURE (2012)
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Sarah K. Knutson et al.
NATURE CHEMICAL BIOLOGY (2012)
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia
Panagiotis Ntziachristos et al.
NATURE MEDICINE (2012)
Epigenetic protein families: a new frontier for drug discovery
Cheryl H. Arrowsmith et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
Wei Qi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2
Sharad K. Verma et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Emerging Epigenetic Targets and Therapies in Cancer Medicine
Relja Popovic et al.
CANCER DISCOVERY (2012)
The role of mutations in epigenetic regulators in myeloid malignancies
Alan H. Shih et al.
NATURE REVIEWS CANCER (2012)
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation
Damian B. Yap et al.
BLOOD (2011)
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Ryan D. Morin et al.
NATURE (2011)
The Polycomb complex PRC2 and its mark in life
Raphael Margueron et al.
NATURE (2011)
Cancer epigenetics reaches mainstream oncology
Manuel Rodriguez-Paredes et al.
NATURE MEDICINE (2011)
EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis
Irina Velichutina et al.
BLOOD (2010)
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Ryan D. Morin et al.
NATURE GENETICS (2010)
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas
Christopher J. Sneeringer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Covalent histone modifications - miswritten, misinterpreted and mis-erased in human cancers
Ping Chi et al.
NATURE REVIEWS CANCER (2010)
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
Tina Branscombe Miranda et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Roles of the EZH2 histone methyltransferase in cancer epigenetics
Jeffrey A. Simon et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2008)
Germinal centres: role in B-cell physiology and malignancy
Ulf Klein et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells
Jing Tan et al.
GENES & DEVELOPMENT (2007)
Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement
IH Su et al.
NATURE IMMUNOLOGY (2003)
Role of histone H3 lysine 27 methylation in polycomb-group silencing
R Cao et al.
SCIENCE (2002)
Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal polycomb sites
B Czermin et al.
CELL (2002)
Histone methyltransferase activity of a Drosophila polycomb group repressor complex
J Müller et al.
CELL (2002)
Chromatin silencing and activation by Polycomb and trithorax group proteins
T Mahmoudi et al.
ONCOGENE (2001)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
The language of covalent histone modifications
BD Strahl et al.
NATURE (2000)
Cutting edge: Polycomb gene expression patterns reflect distinct B cell differentiation stages in human germinal centers
FM Raaphorst et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
